-
Dorsomorphin Workflows for AMPK and BMP Research
2026-09-17
Dorsomorphin, also called Compound C, enables reversible interrogation of AMPK-dependent metabolism, autophagy, BMP signaling, and iron homeostasis. This practical guide combines pathway-specific workflows with time-resolved assay design and troubleshooting for more interpretable cell, embryo, and translational studies.
-
AAL-993 VEGF Receptor Inhibitor Workflow
2026-09-17
AAL-993 supports a mechanism-first workflow that separates VEGFR-dependent endothelial effects from direct tumor-cell responses. This guide combines kinase profiling, angiogenesis assays, migration readouts, and glioma-inspired pathway analysis for more interpretable tumor angiogenesis research.
-
GPR30, Spinal CCK+ Neurons, and Neuropathic Pain
2026-09-16
A recent eLife study identifies GPR30 in spinal cholecystokinin-positive neurons as a key contributor to nerve-injury-induced pain. By combining cell-type analysis, synaptic physiology, projection mapping, and chemogenetic circuit manipulation, the work connects spinal estrogen-receptor signaling with AMPA-mediated sensitization and primary sensory cortex input.
-
Remdesivir (GS-5734): From Assay to Evidence
2026-09-16
Remdesivir and GS-5734 are examined through an evidence-to-assay framework spanning coronavirus antiviral research, Ebola models, and emerging RNA viruses. Learn how to interpret potency, treatment timing, formulation, and cross-virus limitations without overextending the data.
-
Fluconazole Workflows for Antifungal Resistance
2026-09-15
Build reproducible Fluconazole assays around ergosterol disruption, concentration-controlled susceptibility testing, and resistance-aware model design. This guide connects routine Candida albicans experiments with resistant Candida auris workflows and shows how to troubleshoot solubility, endpoint variation, and strain-dependent activity.
-
In Vitro Drug Response: Viability and Cell Death
2026-09-15
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell killing are related but non-interchangeable dimensions of an in vitro cancer drug response. The framework supports more informative assay design by measuring response magnitude, composition, and timing separately rather than treating a single viability endpoint as a complete pharmacological description.
-
Cisplatin (CDDP): Mechanism and Research Workflow
2026-09-14
Cisplatin (CDDP) is a platinum-based DNA-crosslinking agent that damages guanine-rich DNA and can trigger apoptosis. Its value in cancer research depends on controlled formulation, orthogonal readouts, and careful separation of cell, xenograft, and clinical evidence.
-
Pazopanib Hydrochloride: Smarter In Vitro Assays
2026-09-14
Build more informative cancer assays with Pazopanib Hydrochloride (GW786034), a multi-target inhibitor suited to tumor-cell, angiogenesis, and combination-response studies. The workflow separates growth arrest from cell killing so apparent drug sensitivity is not mistaken for cytotoxicity.
-
Pexidartinib (PLX3397) for TAM Research
2026-09-13
Pexidartinib (PLX3397) enables controlled CSF1R-mediated signaling inhibition to investigate macrophage survival, tumor-supportive phenotypes, and anti-tumor responses. This workflow-oriented guide shows how to pair the compound with SPP1-focused assays while separating macrophage depletion from true phenotypic reprogramming.
-
Cisplatin Workflows for Resistance Research
2026-09-12
Build stronger CDDP experiments by linking DNA crosslinking, apoptosis, oxidative stress, and platinum resistance in one workflow. This guide translates Cisplatin handling into practical cell-based assays, mechanistic validation, and tumor growth inhibition in xenograft models.
-
Shenqi Fuzheng Injection in Glioma: SRC/PI3K/AKT
2026-09-11
The reference study combines network pharmacology with cellular and animal experiments to clarify how Shenqi Fuzheng injection suppresses glioma proliferation and migration. Its results identify SRC/PI3K/AKT signaling as a mechanistic focus while also illustrating the strengths and limits of translating multi-component herbal formulations into molecular pathway models.
-
AMPK–SQSTM1 Feedback Under Metabolic Stress
2026-09-11
The 2024 reference study identifies a reciprocal AMPK–SQSTM1/p62 feedback loop that couples lysosomal stress sensing to coordinated activation of AMPK and NFE2L2/NRF2. Its findings explain how metabolically stressed cancer cells strengthen antioxidant defenses and provide a mechanistic framework for interpreting STK11/LKB1 and KEAP1 pathway alterations in lung cancer.
-
Nintedanib (BIBF 1120) in ATRX-Deficient Glioma
2026-09-10
Nintedanib (BIBF 1120) combines VEGFR, FGFR, and PDGFR blockade in one experimentally tractable molecule for angiogenesis, tumor-cell, and genotype-stratified studies. This workflow connects ATRX status with RTK-inhibitor sensitivity while providing practical guidance for viability, apoptosis, combination, and in vivo experiments.
-
Pazopanib Hydrochloride: From Kinase Maps to Translation
2026-09-10
A translational framework for using Pazopanib Hydrochloride and GW786034 to connect multi-kinase biology with more informative cancer response assays, model selection, and clinically relevant strategy.
-
In Vitro Drug Response Metrics in Cancer
2026-09-09
Hannah Schwartz’s dissertation shows that relative viability and fractional viability are distinct measurements of anticancer response, capturing growth inhibition and cell killing with different relationships and timing. Its practical contribution is a more rigorous framework for designing and interpreting in vitro cancer research experiments, including pathway-focused studies of angiogenesis inhibitors.